



---

## **Prasco and Stiefel Sign Distribution and Supply Agreement for Clobetasol Propionate Foam**

**Prasco will exclusively sell and distribute the authorized generic version of Olux® (Clobetasol Propionate Foam 0.05%) as part of an agreement with Stiefel Laboratories, Inc., a GSK Company**

**CINCINNATI, December 22, 2009— Prasco Laboratories** announced today that they have signed a distribution and supply agreement with Stiefel Laboratories Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.

"We are pleased to provide pharmacists and consumers with the authorized generic of Olux® – a trusted brand product," said Prasco Chief Executive Officer E. Thomas Arington. "As a Prasco authorized generic, Clobetasol Propionate Foam will provide patients with the same quality and experience as the brand product," stated Arington. "We are especially pleased to expand our relationship with Stiefel and GSK, leaders in the pharmaceutical industry."

"Through our arrangement with Prasco, GlaxoSmithKline is able to expand patient access to our products by bringing brand quality to the generic marketplace," said Bill Humphries, President, Stiefel, a GSK company. "We are proud of our arrangement with Prasco, a known leader in authorized generics."

Clobetasol Propionate Foam 0.05% is AB-rated, therapeutically equivalent and substitutable for the brand Olux® Foam. Clobetasol Propionate Foam 0.05% is indicated for the short-term treatment of burning and itching caused by moderate to severe skin diseases of the scalp. It may also be used for psoriasis.

Olux® is a registered trademark of Stiefel Laboratories, Inc. Stiefel was acquired by GSK in July 2009.

### **About Prasco**

Prasco provides patients, pharmacists and customers with generic options that deliver the identical brand experience. The Prasco [business model](#) encourages competition and benefits consumers through significant cost savings.

Prasco sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and mail order pharmacies. Prasco operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved facilities for Schedule II-V controlled drug products. For more information, visit [www.prasco.com](http://www.prasco.com).

#### **About Stiefel**

Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people achieve healthy, beautiful skin. Stiefel's dedication and drive for innovation, along with its sole focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as the world leader in the skin health industry. To learn more about Stiefel, visit [www.stiefel.com](http://www.stiefel.com).

#### **About GSK**

**GlaxoSmithKline** – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit [www.gsk.com](http://www.gsk.com)

###

#### CONTACTS:

Glenn Vraniak  
Prasco Laboratories  
513-618-3333  
Website: [www.prasco.com](http://www.prasco.com)  
[www.authorizedgenerics.com](http://www.authorizedgenerics.com)

Erin B. Singer, Director, Global Public Relations  
Stiefel, a GSK company  
678-889-4039  
Website: [www.stiefel.com](http://www.stiefel.com)